MGMT and central nervous system cancer: Glioma biology studies in recent years have discovered a variety of critical genetic and molecular foundations that can influence patient prognosis5, such as IDH mutational status, 1p/19q co-deletion, histone H3-K27M alterations, and MGMT promoter methylation6.